ArriVent BioPharma (NASDAQ:AVBP) Reaches New 52-Week High – Here’s Why

ArriVent BioPharma, Inc. (NASDAQ:AVBP)’s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $27.75 and last traded at $27.25, with a volume of 1333789 shares traded. The stock had previously closed at $25.25.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on AVBP shares. Oppenheimer restated an “outperform” rating and set a $50.00 price target (up from $44.00) on shares of ArriVent BioPharma in a research note on Friday, March 6th. Truist Financial upgraded ArriVent BioPharma to a “strong-buy” rating in a research note on Wednesday, March 25th. Citigroup raised their price target on ArriVent BioPharma from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. Finally, Cantor Fitzgerald started coverage on ArriVent BioPharma in a research note on Monday, December 22nd. They set an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

ArriVent BioPharma Trading Down 6.6%

The firm has a 50 day simple moving average of $23.36 and a two-hundred day simple moving average of $21.74. The company has a market capitalization of $1.13 billion, a PE ratio of -5.77 and a beta of 0.85.

ArriVent BioPharma (NASDAQ:AVBP) last announced its earnings results on Thursday, March 5th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09. Research analysts expect that ArriVent BioPharma, Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of AVBP. Dynamic Technology Lab Private Ltd purchased a new position in shares of ArriVent BioPharma in the 1st quarter valued at approximately $266,000. Woodline Partners LP grew its stake in shares of ArriVent BioPharma by 0.4% in the 1st quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock valued at $2,706,000 after purchasing an additional 576 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ArriVent BioPharma in the 1st quarter valued at approximately $189,000. Legal & General Group Plc grew its stake in shares of ArriVent BioPharma by 8.8% in the 2nd quarter. Legal & General Group Plc now owns 14,790 shares of the company’s stock valued at $322,000 after purchasing an additional 1,197 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of ArriVent BioPharma in the 2nd quarter valued at approximately $206,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.